Cognitive functioning and psychological well-being in breast cancer patients on endocrine therapy

Edit Biro, Zsuzsanna Kahan, J. Kálmán, Orsolya Rusz, Magdolna Pakaski, Tamas Irinyi, Gyöngyi Kelemen, Rita Dudás, Gergely Drotos, Csaba Hamvai

Research output: Contribution to journalArticle

1 Citation (Scopus)


Background/Aim: Anti-cancer therapies may deteriorate cognitive functioning, affective functioning and psychological well-being. Materials and Methods: In this prospective longitudinal pilot study, premenopausal and postmenopausal patients received adjuvant endocrine therapy (ET) (tamoxifen with or without LHRH analog or aromatase inhibitor) or were observed only (control group). At baseline testing and 6, 12 and 24 months thereafter, cognitive, depression and anxiety tests and quality of life (QOL) measurements were performed. Results: Overall, 46 cases were evaluated. None of the studied cognitive parameters differed between the subgroups or changed by time. No differences were found regarding anxiety, depression or QOL measures either. Baseline cognitive test and QOL results were in association with later anxiety and depression. Conclusion: No cognitive impairment was found during the two years of ET. Baseline cognitive scores and QOL dimensions proved good predictors of later anxiety and depression.

Original languageEnglish
Pages (from-to)1381-1392
Number of pages12
JournalIn Vivo
Issue number4
Publication statusPublished - Jan 1 2019


  • Anxiety
  • Breast cancer
  • Cognitive function
  • Depression
  • Endocrine therapy
  • QOL

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Fingerprint Dive into the research topics of 'Cognitive functioning and psychological well-being in breast cancer patients on endocrine therapy'. Together they form a unique fingerprint.

  • Cite this